[Department of Error] Department of Error

McGinley M P, Cohen J A. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 2021; 398: 1184–94—In table 1 of this Therapeutics paper, cenerimod should have had a – symbol in the S1PR5 column. In table 4, the studies for systemic lupus erythematosus should have been listed as: NCT03742037, cenerimod, phase 2, active; NCT02472795, cenerimod, phase 1/2, completed; NCT01294774, KRP203, phase 2, completed; and NCT02307643, amiselimod, phase 1, completed. In the same table, the study for asthma should have been listed as: NCT00785083, fingolimod, phase 2, completed.